Civica plans to produce insulin biosimilars in both vials and prefilled pens and sell them at significantly lower prices than insulins currently on the market, according to a Jan. 31 company press release.
The company plans to set the maximum recommended price to the consumer at $30 per vial and $55 per box of five pen cartridges. Civica products are anticipated to hit the market in 2024 after FDA approval.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
